2020 ESMO临床实践指南:前列腺癌的诊断,治疗和随访

2020-06-25 欧洲肿瘤内科学会 Ann Oncol . 2020 Jun 25;

2020年6月,欧洲肿瘤内科学会(ESMO)发布了前列腺癌的诊断,治疗和随访指南,文是对2015年版指南的更新,主要内涉及前列腺癌的管理建议。

中文标题:

2020 ESMO临床实践指南:前列腺癌的诊断,治疗和随访

英文标题:

Prostate Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up

发布机构:

欧洲肿瘤内科学会

发布日期:

2020-06-25

简要介绍:

2020年6月,欧洲肿瘤内科学会(ESMO)发布了前列腺癌的诊断,治疗和随访指南,文是对2015年版指南的更新,主要内涉及前列腺癌的管理建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 ESMO临床实践指南:前列腺癌的诊断,治疗和随访.pdf)] GetToolGuiderByIdResponse(projectId=1, id=292311c00193350e, title=2020 ESMO临床实践指南:前列腺癌的诊断,治疗和随访, enTitle=Prostate Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up, guiderFrom=Ann Oncol . 2020 Jun 25;, authorId=0, author=, summary=2020年6月,欧洲肿瘤内科学会(ESMO)发布了前列腺癌的诊断,治疗和随访指南,文是对2015年版指南的更新,主要内涉及前列腺癌的管理建议。, cover=https://img.medsci.cn/2020714/1594658490078_2020535.jpg, journalId=0, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology )是1975年成立的非盈利组织,是欧洲领先的专业组织,致力于提高肿瘤内科的专业性,推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Thu Jun 25 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年6月,欧洲肿瘤内科学会(ESMO)发布了前列腺癌的诊断,治疗和随访指南,<span style="color: #373737;">文是对2015年版指南的更新,主要内涉及前列腺癌的管理建议。</span></p> </div> </div> </div>, tagList=[TagDto(tagId=781, tagName=前列腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=781, guiderKeyword=前列腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4337, appHits=288, showAppHits=0, pcHits=1061, showPcHits=4049, likes=0, shares=19, comments=15, approvalStatus=1, publishedTime=Tue Jul 14 01:17:13 CST 2020, publishedTimeString=2020-06-25, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Jul 14 00:41:39 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 19:56:22 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 ESMO临床实践指南:前列腺癌的诊断,治疗和随访.pdf)])
2020 ESMO临床实践指南:前列腺癌的诊断,治疗和随访.pdf
下载请点击:
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1066312, encodeId=4b36106631291, content=。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLD05SCLIc6tibJ8LPD9nARdzRUJ3fKCCibyxmibqkeNbO4hOYN3nHe22jicGmWiaNtDvBJ0R7UFqPm7iajQ/0, createdBy=a93b2031199, createdName=lilili5912, createdTime=Tue Nov 02 18:00:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008957, encodeId=0834100895ee4, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210322/61a71434e1764160b4cd9baee94e7a55/eee5c1c1e8a54e4bb58dbcf51dbb31f0.jpg, createdBy=eb4d1856368, createdName=唐510, createdTime=Wed Aug 18 09:55:00 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008159, encodeId=cd6e1008159b4, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201209/2416a2f8000f4c6f9ca86a500bff21d9/a5506367d87e4670ba4b537445ad01d5.jpg, createdBy=50cb2151142, createdName=188200f478m, createdTime=Sun Aug 15 21:28:11 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004529, encodeId=2dc1100452939, content=很好,学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:48:41 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004528, encodeId=65681004528e5, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:47:14 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-11-02 lilili5912

    。。。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1066312, encodeId=4b36106631291, content=。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLD05SCLIc6tibJ8LPD9nARdzRUJ3fKCCibyxmibqkeNbO4hOYN3nHe22jicGmWiaNtDvBJ0R7UFqPm7iajQ/0, createdBy=a93b2031199, createdName=lilili5912, createdTime=Tue Nov 02 18:00:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008957, encodeId=0834100895ee4, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210322/61a71434e1764160b4cd9baee94e7a55/eee5c1c1e8a54e4bb58dbcf51dbb31f0.jpg, createdBy=eb4d1856368, createdName=唐510, createdTime=Wed Aug 18 09:55:00 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008159, encodeId=cd6e1008159b4, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201209/2416a2f8000f4c6f9ca86a500bff21d9/a5506367d87e4670ba4b537445ad01d5.jpg, createdBy=50cb2151142, createdName=188200f478m, createdTime=Sun Aug 15 21:28:11 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004529, encodeId=2dc1100452939, content=很好,学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:48:41 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004528, encodeId=65681004528e5, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:47:14 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-08-18 唐510

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1066312, encodeId=4b36106631291, content=。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLD05SCLIc6tibJ8LPD9nARdzRUJ3fKCCibyxmibqkeNbO4hOYN3nHe22jicGmWiaNtDvBJ0R7UFqPm7iajQ/0, createdBy=a93b2031199, createdName=lilili5912, createdTime=Tue Nov 02 18:00:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008957, encodeId=0834100895ee4, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210322/61a71434e1764160b4cd9baee94e7a55/eee5c1c1e8a54e4bb58dbcf51dbb31f0.jpg, createdBy=eb4d1856368, createdName=唐510, createdTime=Wed Aug 18 09:55:00 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008159, encodeId=cd6e1008159b4, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201209/2416a2f8000f4c6f9ca86a500bff21d9/a5506367d87e4670ba4b537445ad01d5.jpg, createdBy=50cb2151142, createdName=188200f478m, createdTime=Sun Aug 15 21:28:11 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004529, encodeId=2dc1100452939, content=很好,学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:48:41 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004528, encodeId=65681004528e5, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:47:14 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-08-15 188200f478m

    很好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1066312, encodeId=4b36106631291, content=。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLD05SCLIc6tibJ8LPD9nARdzRUJ3fKCCibyxmibqkeNbO4hOYN3nHe22jicGmWiaNtDvBJ0R7UFqPm7iajQ/0, createdBy=a93b2031199, createdName=lilili5912, createdTime=Tue Nov 02 18:00:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008957, encodeId=0834100895ee4, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210322/61a71434e1764160b4cd9baee94e7a55/eee5c1c1e8a54e4bb58dbcf51dbb31f0.jpg, createdBy=eb4d1856368, createdName=唐510, createdTime=Wed Aug 18 09:55:00 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008159, encodeId=cd6e1008159b4, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201209/2416a2f8000f4c6f9ca86a500bff21d9/a5506367d87e4670ba4b537445ad01d5.jpg, createdBy=50cb2151142, createdName=188200f478m, createdTime=Sun Aug 15 21:28:11 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004529, encodeId=2dc1100452939, content=很好,学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:48:41 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004528, encodeId=65681004528e5, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:47:14 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-08-02 ms4000002095488795

    很好,学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1066312, encodeId=4b36106631291, content=。。。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLD05SCLIc6tibJ8LPD9nARdzRUJ3fKCCibyxmibqkeNbO4hOYN3nHe22jicGmWiaNtDvBJ0R7UFqPm7iajQ/0, createdBy=a93b2031199, createdName=lilili5912, createdTime=Tue Nov 02 18:00:48 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008957, encodeId=0834100895ee4, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210322/61a71434e1764160b4cd9baee94e7a55/eee5c1c1e8a54e4bb58dbcf51dbb31f0.jpg, createdBy=eb4d1856368, createdName=唐510, createdTime=Wed Aug 18 09:55:00 CST 2021, time=2021-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008159, encodeId=cd6e1008159b4, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201209/2416a2f8000f4c6f9ca86a500bff21d9/a5506367d87e4670ba4b537445ad01d5.jpg, createdBy=50cb2151142, createdName=188200f478m, createdTime=Sun Aug 15 21:28:11 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004529, encodeId=2dc1100452939, content=很好,学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:48:41 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004528, encodeId=65681004528e5, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=60285465251, createdName=ms4000002095488795, createdTime=Mon Aug 02 07:47:14 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-08-02 ms4000002095488795

    很好

    0

拓展阅读

2010 ACS 前列腺癌早期筛查指南

美国癌症学会(ACS,American Cancer Society) · 2010-03-01

2010CCO 前列腺癌根治性前列腺切除术病理T3或边缘阳性的辅助放射治疗

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2010-04-15

ESMO临床实践指南:前列腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-01

2008 前列腺癌骨转移临床诊疗专家共识(2008版)

恶性肿瘤骨转移及骨相关疾病临床诊疗专家组 · 2010-05-01

2011EAU前列腺癌诊疗指南

欧洲泌尿外科学会(EAU,European Association of Urology) · 2011-01-01

前列腺癌诊断标准

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2011-07-01